Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

NCT00131911 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

NIH

Sponsor class

Conditions

Gastrinoma
Glucagonoma
Insulinoma
Metastatic Gastrointestinal Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Polypeptide Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma
Somatostatinoma
WDHA Syndrome

Interventions

DRUG: sorafenib tosylate

Sponsor

National Cancer Institute (NCI)